{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:22:01Z","timestamp":1790785321380,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204035"],"award-info":[{"award-number":["82204035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2024ZDZX4015"],"award-info":[{"award-number":["2024ZDZX4015"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011492","name":"Bureau of Science and Technology of Jiangmen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Nutritional Biochemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jnutbio.2025.110138","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:53:04Z","timestamp":1759798384000},"page":"110138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CYP4A14-PPAR\u03b1 axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD"],"prefix":"10.1016","volume":"147","author":[{"given":"Bing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jnutbio.2025.110138_bib0001","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0002","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81:492\u2013542."},{"key":"10.1016\/j.jnutbio.2025.110138_bib0003","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hep.32538","article-title":"Intestinal peroxisome proliferator-activated receptor alpha-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis","volume":"77","author":"Yan","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116617","article-title":"A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis","volume":"174","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0008","first-page":"192","article-title":"Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: a systematic review","volume":"4","author":"Reardon","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0044-1779520","article-title":"UDCA for drug-induced liver disease: clinical and pathophysiological basis","volume":"44","author":"Bessone","year":"2024","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3350\/cmh.2022.0186","article-title":"Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0012","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","article-title":"Roles of PPARs in NAFLD: potential therapeutic targets","volume":"1821","author":"Tailleux","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0013","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/03602530701468573","article-title":"Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation","volume":"39","author":"Hsu","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.addr.2011.03.006","article-title":"The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases","volume":"63","author":"Xu","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0015","article-title":"Cytochrome P450 omega-hydroxylase 4a14 attenuates cholestatic liver fibrosis","volume":"12","author":"Li","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0016","doi-asserted-by":"crossref","first-page":"R934","DOI":"10.1152\/ajpregu.00125.2018","article-title":"High-fat diet-induced obesity and insulin resistance in CYP4a14(-\/-) mice is mediated by 20-HETE","volume":"315","author":"Gilani","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0017","doi-asserted-by":"crossref","first-page":"8994","DOI":"10.29219\/fnr.v67.8994","article-title":"The PPARalpha\/CYP4A14 bile acid pathway is associated with lipid metabolism disorders caused by low birth weight with high-fat diet","volume":"67","author":"Zhou","year":"2023","journal-title":"Food Nutr Res"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788558","article-title":"Ursodeoxycholic acid treatment restores gut microbiota and alleviates liver inflammation in non-alcoholic steatohepatitic mouse model","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0019","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1440-1746.2008.05733.x","article-title":"Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes","volume":"24","author":"Ricchi","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0020","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0021","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41419-025-07664-3","article-title":"Neurotensin promotes hepatic steatosis by regulating lipid uptake and mitochondrial adaptation in hepatocytes","volume":"16","author":"Banerjee","year":"2025","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jnutbio.2025.110138_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12263-025-00768-7","article-title":"Metabolome profiling across liver lobes and metabolic shifts of the MASLD mice","volume":"20","author":"Ma","year":"2025","journal-title":"Genes Nutr"},{"issue":"11","key":"10.1016\/j.jnutbio.2025.110138_bib0024","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cells8111358","article-title":"Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression","volume":"8","author":"Gottlieb","year":"2019","journal-title":"Cells-Basel"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3389\/fphar.2019.00842","article-title":"Ursodeoxycholic acid alters bile acid and fatty acid profiles in a mouse model of diet-induced obesity","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0027","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.metabol.2011.10.023","article-title":"Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice","volume":"61","author":"Tsuchida","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0028","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0029","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0032","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0033","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1210\/en.2005-1132","article-title":"Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression","volume":"147","author":"Patsouris","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0034","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0036","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1476-5381.2011.01263.x","article-title":"20-Hydroxyeicosatetraenoic acid inhibits ATP-induced COX-2 expression via peroxisome proliferator activator receptor-alpha in vascular smooth muscle cells","volume":"163","author":"Liang","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0037","article-title":"The CYP4\/20-HETE\/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease","volume":"15","author":"Hardwick","year":"2024","journal-title":"Front Physiol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0038","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.33549\/physiolres.933512","article-title":"Bile acids, nuclear receptors and cytochrome P450","volume":"65","author":"Jurica","year":"2016","journal-title":"Physiol Res"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0039","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.taap.2015.01.015","article-title":"Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis","volume":"283","author":"Woolbright","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0041","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.toxlet.2014.04.001","article-title":"Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice","volume":"228","author":"Woolbright","year":"2014","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0042","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/toxsci\/kfr177","article-title":"Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicty in mice","volume":"123","author":"Song","year":"2011","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jnutbio.2025.110138_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/501739","article-title":"Regulation of bile acid and cholesterol metabolism by PPARs","volume":"2009","author":"Li","year":"2009","journal-title":"Ppar Res"}],"container-title":["The Journal of Nutritional Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286325003006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955286325003006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:46:44Z","timestamp":1764416804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955286325003006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S0955286325003006"],"URL":"https:\/\/doi.org\/10.1016\/j.jnutbio.2025.110138","relation":{},"ISSN":["0955-2863"],"issn-type":[{"value":"0955-2863","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP4A14-PPAR\u03b1 axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD","name":"articletitle","label":"Article Title"},{"value":"The Journal of Nutritional Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnutbio.2025.110138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110138"}}